Dörner T, Lipsky P E
Department of Medicine, Charité University Medicine, Berlin.
Lupus. 2004;13(5):283-9. doi: 10.1191/0961203304lu1014oa.
CD27 is a useful marker in assessing the number of circulating B cells and B cell subsets because it permits one step identification of the major B cell compartments, CD27- naïve and CD27+ memory B cells as well as CD27high plasma cells. Abnormalities in the distribution ofCD27+ B cell subsets are useful in assessing disease activity in patients with systemic lupus erythematosus (SLE). In particular, the frequency of CD27high plasma cells significantly correlates with lupus activity in both children and adults with SLE. Conventional immunosuppressive therapies affect the number of CD27- naïve B cells and CD27high plasma cells, but do not target CD27+ memory B cells. These results suggest that disease flares may relate to the retention of CD27+ memory B cells after conventional immunosuppressive therapy and that new therapies that target these cells specifically may offer new opportunities to induce remission in SLE.
CD27是评估循环B细胞及B细胞亚群数量的有用标志物,因为它能一步鉴定主要的B细胞区室,即CD27阴性的初始B细胞、CD27阳性的记忆B细胞以及CD27高表达的浆细胞。CD27阳性B细胞亚群分布异常有助于评估系统性红斑狼疮(SLE)患者的疾病活动度。特别是,CD27高表达浆细胞的频率与儿童及成人SLE患者的狼疮活动度显著相关。传统免疫抑制疗法会影响CD27阴性的初始B细胞及CD27高表达浆细胞的数量,但并不针对CD27阳性的记忆B细胞。这些结果表明,疾病复发可能与传统免疫抑制疗法后CD27阳性记忆B细胞的留存有关,而专门针对这些细胞的新疗法可能为诱导SLE缓解提供新机会。